

Brian J. Forsatz Ph.D.

Of Counsel

bforsatz@gibsondunn.com

T: +1 212.351.2488

New York

Brian J. Forsatz, Ph.D. is a litigation attorney in the New York office of Gibson Dunn.

Dr. Forsatz advises clients on complex life sciences patent litigations as well as related regulatory, antitrust, and trade secret issues. He has extensive experience in Hatch-Waxman litigation having counseled numerous biotechnology and pharmaceutical companies in developing effective patent litigation strategies for a wide array of products. Specifically, Dr. Forsatz has lead patent litigations involving small molecule drugs, biological products, medical devices, and laboratory analytical instruments.

Dr. Forsatz has been named a "Rising Star" three times by *Super Lawyers* (2021, 2022, and 2023). In 2021, *Patexia* recognized Dr. Forsatz as among the best performing and most active practitioners in the Hatch-Waxman litigation space since 2021.

Before joining Gibson Dunn, Dr. Forsatz was a litigation attorney at Quinn Emanuel Urquhart & Sullivan since 2013. For over a decade before that, Dr. Forsatz worked as a pharmaceutical research and development scientist. During his pharmaceutical career, he conducted original research and was responsible for several research groups that focused on products for a variety of medical conditions, including asthma, allergies, cardiovascular, anti-inflammation, hematology, and oncology. His practical industry experience is indispensable to clients who seek Dr. Forsatz's assessment as part of their intellectual property strategy.

Representative Experience*:

- Axsome Therapeutics, Inc.: Multiple Hatch-Waxman actions relating to Sunosi® (solriamfetol) drug product.
- Veloxis Pharmaceuticals, Inc.: Multiple Hatch-Waxman actions relating to Envarsus XR® (tacrolimus) drug products.
- Medytox, Inc.: ITC investigation related to botulinum toxin products.
- Jazz Pharmaceuticals, Inc.: Brand versus brand patent infringement and trade secret matters.
- Takeda Pharmaceuticals, Inc.: Multiple Hatch-Waxman actions relating to Iclusig® (ponatinib) drug product.
- Celgene Corporation: More than a dozen Hatch-Waxman actions relating to Revlimid® (lenalidomide) drug products.
- Janssen Pharmaceuticals, Inc. and Mitsubishi Tanabe Pharma: More than a dozen Hatch-Waxman actions relating to Invokana® (canagliflozin)/Invokamet®/Invokamet XR® drug products.
- Celgene Corporation: Multiple Hatch-Waxman actions related to Pomalyst® (pomalidomide) drug products.



Capabilities

Intellectual Property
Antitrust and Competition
Life Sciences
Litigation

Credentials

Education

Fordham University - 2013 Juris Doctor
Seton Hall University - 2007 Doctor of Philosophy
Rutgers University - 1999 Bachelor of Science

Admissions

New York Bar
New Jersey Bar

- Jazz Pharmaceuticals, Inc.: Multiple Hatch-Waxman actions relating to Xyrem® (sodium oxybate) drug product.

**Includes recent experience prior to joining Gibson Dunn.*

Dr. Forsatz received his Juris Doctor from Fordham University School of Law. Before practicing law, Dr. Forsatz received a Ph.D. in chemistry from Seton Hall University and a B.S. in Biochemistry from Rutgers University.

Brian J. Forsatz
Ph.D.
Of Counsel

bforsatz@gibsondunn.com

T: +1 212.351.2488

New York